OPN-7486 is under clinical development by Opna Bio and currently in Phase I for Leukocyte Disorders (White Blood Cell Disorders). According to GlobalData, Phase I drugs for Leukocyte Disorders (White Blood Cell Disorders) have a 97% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how OPN-7486’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

OPN-7486 overview

OPN-7486 is under development for the treatment of histiocytosis. PLX-7486 is a administered orally. It is a small molecule and targets receptor tyrosine kinases Fms and TrkA, TrkB, and TrkC. It was under development for the treatment of advanced solid tumors include advanced pancreatic ductal cancer

Opna Bio overview

Opna Bio is a clinical-stage biopharmaceutical company focuses on the development and discovery of novel oncology therapeutics. Opna Bio is headquartered in Vaud, Switzerland.

For a complete picture of OPN-7486’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.